Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivica Fucek

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Mabs|August 21, 2023
Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography methodThomas Müller, Carolin Tasser, Michael Tesar, et al.
Antibodies (Basel, Switzerland)|February 28, 2022
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell EngagersUwe Reusch, Kristina Ellwanger, Ivica Fucek, et al.
Frontiers in Oncology|June 10, 2017
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb AntibodiesKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Mabs|June 8, 2019
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunityKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Mabs|July 30, 2021
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumorsSusanne Wingert, Uwe Reusch, Stefan Knackmuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid LeukemiaUwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Mabs|August 21, 2023
Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography methodThomas Müller, Carolin Tasser, Michael Tesar, et al.
Antibodies (Basel, Switzerland)|February 28, 2022
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell EngagersUwe Reusch, Kristina Ellwanger, Ivica Fucek, et al.
Frontiers in Oncology|June 10, 2017
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb AntibodiesKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Mabs|June 8, 2019
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunityKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Mabs|April 16, 2015
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.
Mabs|July 30, 2021
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumorsSusanne Wingert, Uwe Reusch, Stefan Knackmuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid LeukemiaUwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Pageof 1